Dear valued customers and friends,

The global pandemic has dominated our personal and professional lives. So first and foremost, I hope that you and your families are healthy and safe. 

At Biomax, we introduced preventive measures early on, and are grateful that we have not had to account for any infections within our team to date. Our employees work mainly from a distance, and use all available digital channels. All on-site meetings are postponed or take place virtually, and our conference participation have been shifted to a virtual level.

Our business continues, and we are noticing that this extraordinary situation is drawing attention to  accelerating digitalization processes. Thus, we were able to support numerous companies, research institutions and clinics in their digitalization efforts this year.

Our business development was particularly characterized by the furthest development of our semantic search platform AILANI and the novel neuroimaging solution NICARA. The great interest in these two product launches shows us that we are on the right track, and we will continue to follow this path with further product launches and innovations in the year to come.

At the same time, we continued, as a partner in several existing and new EU-funded research collaborations, to make valuable contributions to research for new therapies for various diseases as well as Nanotoxicology and safety.

In spite of the adverse circumstances, we are looking forward to the year 2021 with confidence. We look forward to working with you both during and after the pandemic.

Have a safe holiday season!

Klaus Heumann

AILANI. Artificial Intelligent Language Interface

In the first half of 2020 Biomax experts presented the semantic search platform AILANI to a broad audience and highlighted the possibilities and the advantages for customers from industry, research and science using industry-specific case studies. 

In order to support the rapid and successful search for drugs and suitable vaccines against COVID-19 infections Biomax made AILANI available free of charge to research institutes around the world: https://ailani.ai.

In September Biomax announced together with Sagacious IP, Gurugram, India the integration of information on several thousand patents related to therapies and diagnosis submitted by Sagacious IP for AILANI.

Once more at Biodata World Congress in November 2020 Biomax presented the highlights of AILANI. The recording of the expert talk as well as the virtual booth of Biomax can still be accessed via the conference platform.

Features, benefits and our specific offering for AILANI can be found on our new AILANI product website.

NICARA

In Summer 2020 Biomax presented NICARA™, a novel, unique and cost-effective neuroimaging solution focusing on Connectomics at the AAIC Alzheimer's Association International Conference as well as at Bernstein Conference 2020 to a broad audience. In view of the pandemic, these two conferences also took place virtually.

Due to the great interest, Biomax offered several online seminars in the following months to demonstrate the various applications of NICARA to clinicians, scientists and pharmacologists using specially designed use cases.

NICARA can be accessed and tested free here.

COVID-19

In view of the current pandemic Biomax contributed to the research response on COVID-19/SARS-CoV-2 in multiple ways. As partner in the EU-project PREPARE (Platform for European Preparedness Against (Re-)emerging Epidemics) and member of the COVID-19 Disease Map Collaboration Biomax applied literature mining and knowledge integration and made the results publicly available with the scientific assistant AILANI for COVID-19 research.

Additionally, Biomax  applied its System Medicine implementation of the BioXM Knowledge Management and its Viscovery AI-based machine learning to research persistent symptoms in COVID-19 patients in close cooperation with its partner CIRO+.

Mental disorders

In the year 2020 Biomax invested into three outstanding projects on the development of clinical decision support systems (CDSS) for neurological and mental disorders, MS-CONNECT, DEVoTED and TranSYS.

With its expertise and the underlying NeuroXM Brain Science Suite, Biomax helps identify and characterize patient populations and predict treatment outcomes.

Due to the lively interest in the webinar series on AILANI and NICARA, Biomax plans to offer online seminars again next year. Further information will be published on the company website in course of the year. 

In addition, Biomax plans to participate in several scientific and industrial conferences, again. Dates and further information will also be announced on the website.